Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs ASP-1948 (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma Global Development

    • Most Recent Events

    • 05 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 28 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top